Glaucoma Service, Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USA.
J Glaucoma. 2012 Sep;21(7):460-8. doi: 10.1097/IJG.0b013e318218287f.
To compare outcomes of selective laser trabeculoplasty (SLT) with drug therapy for glaucoma patients in a prospective randomized clinical trial.
Sixty-nine patients (127 eyes) with open-angle glaucoma or ocular hypertension were randomized to SLT or medical therapy. Target intraocular pressure (IOP) was determined using the Collaborative Initial Glaucoma Treatment Study formula. Patients were treated with SLT (100 applications 360 degrees) or medical therapy (prostaglandin analog). Six visits over 1 year followed initial treatment. If target IOP range was not attained with SLT, additional SLT was the next step, or in the medical arm additional medications were added.
IOP; secondary: number of steps.
Sixty-nine patients were treated. Data collection terminated with 54 patients reaching 9 to 12-months follow-up. Twenty-nine patients were in the SLT group, 25 patients in the medical group. Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm. By last follow-up, 11% of eyes received additional SLT, 27% required additional medication. There was not a statistically significant difference between the SLT and medication groups.
IOP reduction was similar in both arms after 9 to 12-months follow-up. More treatment steps were necessary to maintain target IOP in the medication group, although there was not a statistically significant difference between groups. These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.
在一项前瞻性随机临床试验中比较选择性激光小梁成形术(SLT)与药物治疗青光眼患者的结果。
将 69 例(127 只眼)开角型青光眼或高眼压患者随机分为 SLT 组或药物治疗组。目标眼压(IOP)采用协作性初始青光眼治疗研究公式确定。患者接受 SLT(100 次 360 度应用)或药物治疗(前列腺素类似物)。初始治疗后 1 年内进行 6 次随访。如果 SLT 未达到目标眼压范围,则下一步是进行额外的 SLT,或者在药物治疗组中添加其他药物。
IOP;次要结局:步骤数。
共治疗 69 例患者。54 例患者达到 9 至 12 个月随访时,数据收集结束。29 例患者在 SLT 组,25 例患者在药物组。所有眼的 SLT 组基线平均 IOP 为 24.5mmHg,药物组为 24.7mmHg。SLT 组最后一次随访时双眼平均 IOP 为 18.2mmHg(降低 6.3mmHg),药物组为 17.7mmHg(降低 7.0mmHg)。最后一次随访时,11%的眼接受了额外的 SLT,27%需要额外的药物治疗。SLT 组和药物组之间无统计学显著差异。
9 至 12 个月随访后,两组的 IOP 降低相似。药物组维持目标眼压需要更多的治疗步骤,尽管两组之间无统计学显著差异。这些结果支持 SLT 作为开角型青光眼或高眼压的安全有效初始治疗选择。